2013-08-09T13:22:48-05:00 2012-12-31 521855942 TATE AND TRYON 2021 L STREET NW SUITE 400 WASHINGTON DC 20036 990 2012-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 PAUL AINES 5714831300 2013-08-09 1 DEBORAH G KOSNETT P00290720 2022932200 2012 2016-02-24 21:20:13Z ASCO ALLEN LICHTER MD 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 146059607 0 X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, CONTINUED FROM PAGE 1: PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 18 17 346 1200 11870814 3049601 7731584 9951001 72435660 73138765 2649887 4566995 327026 771150 83144157 88427911 1923073 1729260 0 0 26305710 31364730 520215 110025 5798257 43619831 44890049 72368829 78094064 10775328 10333847 162402498 177197733 103704424 104485526 58698074 72712207 X ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY CARE.ASCO VISION STATEMENTS:-- ALL CANCER PATIENTS WILL HAVE LIFELONG ACCESS TO HIGH QUALITY, EFFECTIVE, AFFORDABLE AND COMPASSIONATE CARE.-- THE MOST ACCURATE CANCER INFORMATION WILL BE AVAILABLE SO THAT PATIENTS AND PHYSICIANS CAN MAKE INFORMED DECISIONS ABOUT CANCER PREVENTION AND TREATMENT.-- INFORMATION WE LEARN FROM EVERY PATIENT WILL BE USED TO ACCELERATE PROGRESS AGAINST CANCER.-- RESOURCES WILL EXIST TO ATTRACT THE BEST CLINICIANS AND INVESTIGATORS TO PROVIDE OPTIMAL PATIENT CARE AND TO CONDUCT TRANSFORMATIVE RESEARCH. --ASCO WILL BE RECOGNIZED AS THE MOST TRUSTED SOURCE OF CANCER INFORMATION WORLDWIDE. 0 0 31114360 1185540 41335902 EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS AND PROFESSIONAL DEVELOPMENT: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A WIDE VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF DIFFERENT FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCE KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE.THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS,JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THEMODERN-DAY PRACTICE OF ONCOLOGY.WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM.ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS.HIGHLIGHTS OF THE 2012 ACTIVITIES INCLUDE: OVER 31,000 PEOPLE ATTENDED THE 2012 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES,CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2012 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2012 ANNUAL MEETING FEATURED OVER 220 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 4,500 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY.-IN 2012, ASCO HELD THREE "BEST OF ASCO" MEETINGS, WHICH COVERED THE MOST GROUND BREAKING SCIENCE RELEASED AT ASCO'S ANNUAL MEETING. NEARLY 1,200 ATTENDEES PARTICIPATED IN THESE MEETINGS.-IN 2012, ASCO OFFERED ITS INAUGURAL QUALITY CARE SYMPOSIUM, WITH OVER 650 PEOPLE IN ATTENDANCE.-IN 2012, ASCO WAS THE LEAD SPONSOR OF SEVERAL THEMATIC SYMPOSIA FOCUSING ON BREAST, GASTROINTESTINAL, AND GENITOURINARY CANCERS, WHICH COLLECTIVELY DREW NEARLY 6,500 ATTENDEES. ALL 2012 ASCO MEETINGS AND SYMPOSIA WERE OPEN TO THE GENERAL PUBLIC.-IN 2012, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD. THESE MEETINGS INCLUDE:- ANNUAL MEETING- BEST OF ASCO CHICAGO- BEST OF ASCO BOSTON- BEST OF ASCO SAN DIEGO- ASCO'S QUALITY CARE SYMPOSIUM- GI CANCERS SYMPOSIUM- GU CANCERS SYMPOSIUM- BREAST CANCER SYMPOSIUM- MARKERS IN CANCER- ASCO/AACR METHODS WORKSHOPINTERNATIONAL AFFAIRS MEETINGS AND COURSES- BEST OF ASCO INTERNATIONAL (22)- JOINT SYMPOSIA (17)- ADVANCED CANCER COURSES (4)- MULTIDISCIPLINARY CANCER MANAGEMENT COURSES (2)ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. 11851777 57500 27067942 EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES TWO EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED,PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. THE JOURNALS INCLUDE ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS,AND OTHER WORK THAT RELATES TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THEREBY INCREASING ITS USE INTERNATIONALLY.PROGRAM SERVICE ACCOMPLISHMENTS:-IN 2012 JOURNAL OF CLINICAL ONCOLOGY HAD 24,100 ANNUAL SUBSCRIBERS. ADDITIONALLY, AS REPORTED BY THOMSON REUTERS IN ITS 2011 JOURNAL CITATION REPORT, JCO'S IMPACT FACTOR OF 18.732 RANKED IT #53 OUT OF 8,336 JOURNALS MEASURED AND #5 IN THE ONCOLOGY CATEGORY (196 JOURNALS MEASURED). JCO RECEIVED 120,262 TOTAL CITATIONS IN 2011, WHICH RANKED IT #23 OVERALL AND #2 IN THE ONCOLOGY CATEGORY. JCO'S EIGENFACTOR SCORE OF 0.39463 (A MEASURE OF WHAT TYPES OF CITATIONS WERE GENERATED) RANKED IT #16 OVERALL AND #1 IN THE ONCOLOGY CATEGORY. THE IMPACT FACTOR, TOTAL CITATIONS, AND EIGENFACTOR SCORES ARE ALL REFLECTIONS OF THE VALUE RESEARCHERS FIND IN JCO CONTENT.IN 2012, JOURNAL OF ONCOLOGY PRACTICE (JOP) WAS ACCEPTED FOR INDEXING IN MEDLINE, THE PREMIER BIBLIOGRAPHIC DATABASE OF THE U.S. NATIONAL LIBRARY OF MEDICINE (NLM). THE INCLUSION OF JOP IN MEDLINE GIVES AN INDICATION OF ITS GROWING PROMINENCE AND REPUTATION IN ONCOLOGY AND IS A REFLECTION OF THE VERY HIGH QUALITY OF ITS PUBLISHED ARTICLES. 7936911 0 2113234 QUALITY: THE ASCO QUALITY DEPARTMENT IS RESPONSIBLE FOR THE DEVELOPMENT OF EVIDENCE-BASED GUIDELINES, DEVELOPING AND VALIDATING QUALITY MEASURES IN ONCOLOGY, QUALITY IMPROVEMENT AND MEASUREMENT. IN 2012, ASCO, WITH ITS RELATED ORGANIZATION, INSTITUTE FOR CLINICAL EXCELLENCE, LLC, ENTERED THE ASSESSMENT PHASE OF CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. THE ASSESSMENT PHASE FOCUSES ON THE DEVELOPMENT OF A BREAST-CANCER SPECIFIC PROTOTYPE, WHICH WILL HELP DETERMINE AND OVERCOME THE BARRIERS IN DEVELOPING A FULL SYSTEM.PROGRAMS INCLUDE: - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING HAWAII, ALASKA, GUAM, AND PUERTO RICO ARE ENROLLED IN THE PROGRAM.- QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE.THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO:- PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS.- PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES.- REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO THE DEMONSTRATION OF QUALITY.THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A SPECIAL-PURPOSE LIMITED LIABILITY CORPORATION (LLC), THE INSTITUTE FOR CLINICAL EXCELLENCE, LLC (D/B/A QOPI CERTIFICATION PROGRAM). THE SOLE MEMBER OF THIS LLC IS ASCO AND THE PRESIDENT IS ASCO'S CHIEF EXECUTIVE OFFICER. NEW GUIDELINES AND ONGOING UPDATES. ASCO NOW HAS 39 PUBLISHED PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. AN ADDITIONAL 11 GUIDELINES ARE IN DEVELOPMENT, ALONG WITH 6 UPDATES TO EXISTING GUIDELINES. IN ADDITION, ASCO HAS ENDORSED TWO GUIDELINES DEVELOPED BY OUTSIDE ORGANIZATIONS. 10395710 486220 2621687 CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE IN ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY.CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE.PROGRAM SERVICE ACCOMPLISHMENTS: IN 2012, ASCO'S ACTIVITIES INCLUDED EFFORTS IN THE FOLLOWING AREAS:- WISE STEWARDSHIP OF LIMITED HEALTHCARE RESOURCES - BROAD EFFORTS TO BETTER STEWARD LIMITED HEALTH CARE RESOURCES INCLUDED ASCO PARTICIPATION IN THE AMERICAN BOARD OF INTERNAL MEDICINE'S "CHOOSING WISELY" CAMPAIGN, WHICH IS AIMED AT REDUCING OR ELIMINATRING COMMONLY USED SERVICES THAT ARE OF QUESTIONABLE VALUE. ASCO WAS ONE OF NINE MEDICAL SPECIALTY SOCIETIES TO PARTICIPATE. ASCO'S COST OF CARE TASK FORCE IS IN THE PROCESS OF WORKING WITH QUALITY AND EDUCATION TEAMS TO DISSEMINATE ITS RECOMMENDATIONS TO ONCOLOGISTS AND IS IDENTIFYING ADDITIONAL ITEMS FOR THE COMING YEAR.ASCO EXPANDED ITS POLICY WORK THIS YEAR TO ADDRESS CANCER CARE AND RESEARCH ISSUES IN THE AREAS OF SURVIVORSHIP, TOBACCO USE, HEREDITARY CANCER RISK, AND CARE FOR PATIENTS WITH ADVANCED CANCER. ALSO, AS PART OF A COMPREHENSIVE EFFORT TO DETERMINE WORKFORCE CAPACITY TO MEET PROJECTED INCREASES IN CANCER INCIDENCE AND TO IDENTIFY INNOVATIVE CARE MODELS, ASCO LAUNCHED A MULTI-PRONGED RESEARCH EFFORT TO ESTABLISH AN ONCOLOGY CENSUS, IDENTIFY TRENDS IN PRACTICE ECONOMICS, AND DOCUMENT CARE PATTERNS. FINALY, THE SOCIETY WORKED IN COLLABORATION WITH FDA AND OTHER ONCOLOGY STAKEHOLDERS TO REFINE CLINICAL ENDPOINTS USED IN CANCER CLINICAL TRIALS AND TO ADDRESS THE ONGOING CHALLENGES PRESENTED BY PERSISTENT SHORTAGES OF CRITICAL CHEMOTHERAPY DRUGS. THE STATE/REGIONAL AFFILIATE PROGRAM: THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL.FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCHASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH. STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC).ORIGINAL DATA COLLECTIONASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. IN 2012, ASCO COMPLETED A WORKFORCE CENSUS AND A COMPREHENSIVE ASSESSMENT OF EMERGING ONCOLOGY PRACTICE TRENDS. WORKFORCE CENSUS AND PRACTICE TREND ANALYSIS WILL BECOME AN ANNUAL EFFORT TO CLOSELY MONITOR THE RESEARCH AND PRACTICE ENVIRONMENTS AND WILL PROVIDE AN IMPORTANT FOUNDATION FOR DETERMINING IMPACT OF CHANGES OCCURRING AS A RESULT OF HEALTHCARE REFORM IN THE UNITED STATES. MEMBER SERVICESMEMBER SERVICES WORKS TO SUPPORT ASCO'S MORE THAN 30,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS.ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AND OPPORTUNITIES TO CREATE GROUPS. COMMUNICATIONS AND PATIENT INFORMATION:ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION,AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILYMEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY.THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER.IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET.FIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST.CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA.WHAT TO KNOW: ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS.RESEARCH AND MEETINGS: INFORMATION ON ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS.MULTIMEDIA: MEDICAL ILLUSTRATIONS, MOBILE APP, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING.EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH.CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT.ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS.CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, SURVIVORSHIP, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. 10395710 486220 2621687 61298758 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 1 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1 505 0 1 346 1 1 1 0 0 0 0 0 0 0 0 0 X 18 17 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 VA NY X PAUL AINES CPA CFO 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 SANDRA SWAIN MD 08-12 1.00 1.00 X X 0 0 0 CLIFFORD HUDIS MD 09-12 1.00 0.00 X X 3333 0 0 JAMES ABBRUZZESE MD 1.00 0.00 X 0 0 0 SMITA BHATIA MD 1.00 0.00 X 0 0 0 GARY COHEN MD 1.00 0.00 X 0 0 0 SUSAN COHN MD 09-12 1.00 0.00 X X 0 0 0 STEPHEN GRUBBS MD 1.00 0.00 X 0 0 0 DANIEL HAYES MD 1.00 0.00 X 0 0 0 HAGOP KANTARJIAN MD 1.00 0.00 X 0 0 0 MICHAEL LINK MD 10-13 1.00 0.00 X 0 0 0 GARY LYMAN MD 1.00 0.00 X 0 0 0 MARTIN MURPHY JR PHD DMEDSC 1.00 1.00 X 0 0 0 LORI PIERCE MD 1.00 0.00 X 0 0 0 CAROLYN RUNOWICZ MD 1.00 0.00 X 0 0 0 FRANCES SHEPHERD MD 1.00 0.00 X 0 0 0 LILLIAN SIU MD 1.00 0.00 X 0 0 0 JULIE VOSE MD 1.00 0.00 X 0 0 0 ERIC WINER MD 1.00 0.00 X 0 0 0 ROBIN ZON MD 1.00 0.00 X 0 0 0 ALLEN LICHTER MD 33.50 4.00 X X 779040 0 20624 PAUL AINES CPA 33.50 4.00 X 300127 0 37292 DINA MICHELS ESQ 33.50 4.00 X 473165 0 38214 NANCY DALY MSMPH 1.00 36.50 X 212312 0 30150 JEAN COLVARD 37.50 0.00 X 210112 0 23851 DEBORAH KAMIN RNPHD 37.50 0.00 X 238689 0 37014 BERNIE KHOO 37.50 0.00 X 326815 0 37292 CARA MOLINARI 37.50 0.00 X 169719 0 19889 THERESA VAN SCHAIK 37.50 0.00 X 186086 0 27979 SUZANNE BRACH 37.50 0.00 X 205812 0 29537 KRISTIN LUDWIG 37.50 0.00 X 228270 0 18037 KAY NOLL 37.50 0.00 X 198968 0 21187 DOUGLAS PYLE 37.50 0.00 X 187681 0 33390 ROBERT HAUSER PHARMD PHD 37.50 0.00 X 267059 0 27292 3987188 0 401748 60 0 1 0 THE CORKERY GROUP 260 FIFTH AVE NEW YORK NY 10001 PUBLIC RELATIONS 1094954 POLSINELLI SHUGHART PC 1152 15TH STREET NW WASHINGTON DC 20005 LEGAL 570763 THE MERZ GROUP 1570 MCDANIEL DR WEST CHESTER PA 19380 BRANDING 468724 ASTUTE TECHNOLOGY 11718 BOWMEN GREEN DR RESTON VA 20190 VIDEO RECORDING 382962 BECKSTEIN PRODUCTION LLC 12415 ROUSSEAU TERRACE NORTH POTOMAC MD 20878 CREATIVE DEVELOPMENT 304567 12 9951001 9951001 EDUCATION MTGS & PROD 900099 24845353 24845353 PUBLICATIONS 511190 12840162 12840162 ADVERTISING 541800 12253094 12253094 MEMBERSHIP 900099 11354154 11354154 EXHIBITS 900099 8652782 8652782 3193220 3057622 135598 73138765 3044576 3044576 943146 943146 862100 1485278 -623178 -623178 -623178 57668837 56146418 1522419 1522419 1522419 MAILING LIST 511120 345882 345882 OTHER 900099 105300 105300 451182 88427911 60750073 11870814 5856023 1421990 1421990 307270 307270 3171703 2216881 633675 321147 22478323 16281445 3366127 2830751 1425319 997723 285064 142532 2579259 1805481 515852 257926 1710126 1197088 342025 171013 750659 520431 230228 162385 162385 110469 110469 110025 110025 613090 613090 11066178 10228472 699345 138361 250549 214089 36460 585816 439362 137812 8642 3163705 2467305 696400 5557535 4468151 1089384 3198962 2745336 443996 9630 7844592 7321146 523446 2694916 1856191 778625 60100 523565 227575 295990 UBI TAX 597335 597335 PRINTING & PRODUCTION 3881653 3881653 DEVELOPMENT FEE TO CCF 1737380 1737380 POSTAGE & SHIPPING 1704492 1677242 27250 446768 316123 119895 10750 78094064 61298758 10997049 5798257 300 300 6579091 6772025 5459559 4394111 3712320 3001853 66511333 10710731 57575153 55800602 88475115 104851167 35506 0 565454 2377675 162402498 177197733 4141575 5034542 16505330 16686023 48050000 38400000 35007519 44364961 103704424 104485526 X 58698074 72712207 58698074 72712207 162402498 177197733 X 10333847 3387728 292558 X X 0 1 X 1 0 X 9732535 9749125 8931139 7731584 9951001 46095384 57902080 57163871 61001326 61722689 60750073 298540039 257198 155397 235462 386588 345882 1380527 67891813 67068393 70167927 69840861 71046956 346015950 14269952 13762781 12940190 10563934 13094217 64631074 0 14269952 13762781 12940190 10563934 13094217 64631074 281384876 2234994 1248387 848971 3354163 3987722 11674237 1237990 1445377 2794100 1677713 1888008 9043188 3472984 2693764 3643071 5031876 5875730 20717425 73056 73056 71364797 69762157 73810998 74872737 76995742 366806431 0.76710 0.76070 0.05650 0.05580 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1320 168779 170099 64706565 64876664 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 152632 148210 148941 170099 619882 250000 250000 250000 250000 1000000 1500000 214 1320 1534 15916 15916 7342677 7342677 47693486 5358296 42335190 11475170 5352435 6122735 55800602 LIABILITY UNDER INTEREST RATE SWAP AGREEMENT 18764961 TAXABLE BOND PAYABLE 25600000 44364961 X 92980385 3387728 1777836 5165564 87814821 613090 613090 88427911 78966252 1485278 1485278 77480974 613090 613090 78094064 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. AT A MINIMUM, THE 2006 THROUGH 2012 TAX YEARS ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE TO PART VIII 1,485,278. GAIN ON VALUE OF INTEREST RATE SWAP 292,558. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE TO PART VIII 1,485,278. 1 NORTH AMERICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 4555 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 7529 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 39628 RUSSIA AND NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 11531 EUROPE 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 39297 SOUTH AMERICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 45529 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 66618 MIDDLE EAST & NORTH AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 25973 SOUTH ASIA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 45710 0 0 0 0 0 0 240660 45710 286370 EUROPE CONTRIBUTION TO SUPPORT GLOBAL PROGRAMS ON BREAST CANCER 20900 1 0 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD CENTRAL AMERICA AND THE CARIBBEAN 1 1100 CHECK 3099 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH ASIA 8 9100 CHECK 26967 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD EAST ASIA AND THE PACIFIC 2 2400 CHECK 10548 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD RUSSIA AND NEWLY INDEPENDENTS STATES 3 3500 CHECK 12975 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD MIDDLE EAST & AFRICA 1 1100 CHECK 3611 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH AMERICA 2 2300 CHECK 9141 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SUB-SAHARAN AFRICA 5 5900 CHECK 22961 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD EUROPE 1 1200 CHECK 3355 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) - THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS OF REVIEW USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, AND TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT AND SUBMIT ONE-YEAR REPORTS. 1 GRAHAM PELTON CONSULTING 39 BEECHWOOD RD SUMMIT NJ 07901 FUNDRAISING CONSULTANT 0 0 110025 -110025 110025 -110025 VA NY EXPLANATION OF FUNDRAISING PAYMENTS SCHEDULE G, PART I, LINE 2B, COLUMN (V) PAYMENTS TO GRAHAM PELTON WERE FOR FUNDRAISING SERVICES FOR ASCO'S 501(C)(3) RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY TO DETERMINE FUNDRAISING BEST PRACTICES - NO REVENUE WAS RECEIVED. 1 HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW 310 WASHINGTON DC 20036 521485477 501(C)(3) 5000 CONTRIBUTION FRIENDS OF CANCER RESEARCH 3299 K ST NW WASHINGTON DC 20007 521983273 501(C)(3) 15000 CONTRIBUTION AMERICAN COLLEGE OF SURGEONS 633 NORTH ST CLAIR CHICAGO IL 60611 362192800 501(C)(3) 25000 CONTRIBUTION NATIONAL ACADEMY OF SCIENCES 2101 CONSTITUTION AVENUE NW WASHINGTON DC 20418 530196932 501(C)(3) 61000 CONTRIBUTION BROOKINGS INSTITUTION 1775 MASSACHUSETTS AVE WASHINGTON DC 20036 530196577 501(C)(3) 10000 CONTRIBUTION WASHINGTON HOSPITAL CENTER 110 IRVING ST NW WASHINGTON DC 20010 521272129 501(C)(3) 217624 CONTRIBUTION KOMEN NAT'L RACE FOR THE CURE 1911 N FORT MYER DR 112 ARLINGTON VA 22209 751835298 501(C)(3) 25000 CONTRIBUTION CONQUER CANCER FOUNDATION 2318 MILL ROAD 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 764000 CONTRIBUTION MEMORIAL SLOAN KETTERING CANCER CENTER PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 94790 CONTRIBUTION INDIANA UNIVERSITY 620 UNION DRIVE INDIANAPOLIS IN 46202 356001673 501(C)(3) 9374 CONTRIBUTION STANFORD UNIVERSITY 1000 WELCH ROAD 301 STANFORD CA 94301 941156365 501(C)(3) 98387 CONTRIBUTION PREVENT CANCER FOUNDATION 1600 DUKE ST 500 ALEXANDRIA VA 22314 521429544 501(C)(3) 5000 CONTRIBUTION CANCERCARE 275 7TH AVE NEW YORK NY 10001 131825919 501(C)(3) 5000 CONTRIBUTION BREAST CANCER RESEARCH FOUNDATION 654 MADISON AVE 1209 NEW YORK NY 10021 133727250 501(C)(3) 15000 CONTRIBUTION NATIONAL COALITION FOR CANCER SURVIVORSHIP 1010 WAYNE AVE 770 SILVER SPRING MD 20910 850357897 501(C)(3) 25000 CONTRIBUTION UNIVERSITY OF CHICAGO 1427 E 60TH SUITE 120 CHICAGO IL 60637 362177139 501(C)(3) 46795 CONTRIBUTION 16 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO 501(C)(3) ORGANIZATIONS THAT SERVE THE CANCER COMMUNITY. X 1 1 X X X X X X 0 0 0 0 0 0 0 1 1 1 ALLEN LICHTER MD 669040 0 95000 0 15000 0 18750 0 1874 0 799664 0 0 0 PAUL AINES CPA 294127 0 6000 0 0 0 18750 0 18542 0 337419 0 0 0 DINA MICHELS ESQ 473165 0 0 0 0 0 18750 0 19464 0 511379 0 0 0 NANCY DALY MSMPH 205986 0 6326 0 0 0 15763 0 14387 0 242462 0 0 0 JEAN COLVARD 206112 0 4000 0 0 0 16542 0 7309 0 233963 0 0 0 DEBORAH KAMIN RNPHD 231689 0 7000 0 0 0 17550 0 19464 0 275703 0 0 0 BERNIE KHOO 322815 0 4000 0 0 0 18750 0 18542 0 364107 0 0 0 CARA MOLINARI 168219 0 1500 0 0 0 12675 0 7214 0 189608 0 0 0 THERESA VAN SCHAIK 181086 0 5000 0 0 0 13650 0 14329 0 214065 0 0 0 SUZANNE BRACH 200312 0 5500 0 0 0 15150 0 14387 0 235349 0 0 0 KRISTIN LUDWIG 223270 0 5000 0 0 0 16725 0 1312 0 246307 0 0 0 KAY NOLL 193968 0 5000 0 0 0 14381 0 6806 0 220155 0 0 0 DOUGLAS PYLE 182681 0 5000 0 0 0 13950 0 19440 0 221071 0 0 0 ROBERT HAUSER PHARMD PHD 252059 0 15000 0 0 0 8750 0 18542 0 294351 0 0 0 PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED TO THE CEO, WHICH IS CONSIDERED PART OF THE CEO'S COMPENSATION AND ADDRESSED IN THE CEO'S WRITTEN EMPLOYMENT CONTRACT. THE HOUSING ALLOWANCE IS TREATED AS TAXABLE COMPENSATION. PART I, LINE 7 PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. PART I, LINE 8 CERTAIN AMOUNTS PAID OR ACCRUED TO THE CEO AND THE VP/GC WERE PURSUANT TO A CONTRACT THAT WAS SUBJECT TO THE INITIAL CONTRACT EXCEPTION DESCRIBED IN TREAS. REGS. SECTION 53.4958-4(A)(3). A INDUSTRIAL DEVELOPMENT AUTHORITY CITY OF ALEXANDRIA 521381432 01530LAD2 2012-08-01 38400000 BUY/BLDOUT 5 FLS HQ BLDG 0 0 0 A 38400000 38400000 2008 0 0 1 1 A 0 0 1 1 0 0.00000 0.00500 0.00500 0 0 1 A 0 0 0 0 1 1 DEPFA BANK 30.000000000000 0 0 0 0 1 A 1 PART IV, QUESTION 3: ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH DEPFA BANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THESE INTEREST RATE SWAP AGREEMENTS QUALIFY AS A DERIVATIVE INSTRUMENT AND ARE USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2012, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH VOTING RIGHTS: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND 14 DIRECTORS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED BY VOTING MEMBERS OF ASCO AND HAVE THE SAME VOTING RIGHTS. THE CHIEF EXECUTIVE OFFICER (CEO) IS AN EX-OFFICIO, NON-VOTING MEMBER OF THE BOARD OF DIRECTORS. ADDITIONALLY, THE CHAIR OF THE BOARD OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX EXEMPT RELATED ORGANIZATION OF ASCO) IS AN EX-OFFICIO, NON-VOTING MEMBER OF THE BOARD OF DIRECTORS OF ASCO. DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. DURING THE REPORTING YEAR, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THEIR FINAL YEAR OF THEIR TERM. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE CATEGORIES OF MEMBERSHIP AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR ACTIVE MEMBER STATUS. OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G., EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER ARE ELIGIBLE FOR ACTIVE MEMBER STATUS. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, SERVE ON ALL COMMITTEES OF ASCO, AND VOTE AND HOLD OFFICE IN ASCO. 2. INTERNATIONAL CORRESPONDING MEMBERS. 2.A. INTERNATIONAL CORRESPONDING MEMBERS ARE EXPERIENCED PHYSICIANS WHO ARE ELIGIBLE TO BE FULL MEMBERS, BUT WHO RESIDE IN A DEVELOPING NATION OR A NATION WITH A LOW PER-CAPITA INCOME, AS DEFINED BY THE BOARD OF DIRECTORS FROM TIME TO TIME. 2.B. RIGHTS OF INTERNATIONAL CORRESPONDING MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. INTERNATIONAL CORRESPONDING MEMBERS MAY NOT SERVE ON COMMITTEES OF ASCO, AND MAY NOT VOTE OR HOLD OFFICE IN ASCO. 3. ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS. 3.A. ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS ARE OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G., EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANK WHO ARE NOT ELIGIBLE TO BE A FULL MEMBER AND WHO HAVE A PREDOMINANT INTEREST IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 3.B. RIGHTS OF ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS AND TO SERVE ON ALL COMMITTEES OF ASCO. ACTIVE-ALLIED MEMBERS MAY NOT VOTE OR HOLD OFFICE IN ASCO. 4. AFFILIATED HEALTH PROFESSIONAL MEMBERS. 4.A. AFFILIATED HEALTH PROFESSIONAL MEMBERS ARE AFFILIATED HEALTH PROFESSIONALS IN ONCOLOGY, INCLUDING ONCOLOGY NURSES, PHYSICIAN ASSISTANTS, AND OTHER HEALTH SPECIALISTS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO THE CARE AND TREATMENT OF PATIENTS WITH NEOPLASTIC DISEASES. MEMBERSHIP IS LIMITED TO THOSE PERSONNEL WHO FUNCTION AS INTEGRAL MEMBERS OF A TEAM OF ONCOLOGISTS RESPONSIBLE FOR THE CARE OF SUCH PATIENTS OR WHO ENGAGE IN THE CONDUCT OF CLINICAL TRIALS. ELECTION TO MEMBERSHIP IS BASED ON EXPERIENCE IN AND CONTRIBUTIONS TO THE FIELD OF ONCOLOGY. ADDITIONALLY, AFFILIATED HEALTH PROFESSIONAL MEMBER STATUS INCLUDES INDIVIDUALS WHO HOLD LEADERSHIP POSITIONS OR HAVE TAKEN A DISTINGUISHED LEADERSHIP ROLE IN A NATIONALLY OR INTERNATIONALLY RECOGNIZED NOT-FOR-PROFIT, TAX-EXEMPT ORGANIZATION DEDICATED TO CANCER PATIENT ADVOCACY OR SURVIVORSHIP. 4.B. RIGHTS OF AFFILIATED HEALTH PROFESSIONAL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS AND SERVE ON ALL COMMITTEES OF ASCO. AFFILIATED HEALTH PROFESSIONAL MEMBERS MAY NOT VOTE OR HOLD OFFICE IN ASCO. 5. EMERITUS MEMBERS. 5.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 65, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 5.B. RIGHTS OF EMERITUS MEMBERS INCLUDE BEING EXEMPT FROM MEMBERSHIP DUES. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN ALL RIGHTS AND PRIVILEGES OF FULL MEMBER STATUS, EXCEPT THE HOLDING OF OFFICE. EMERITUS MEMBERS WHO WERE PREVIOUSLY ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBERS RETAIN ALL THE RIGHTS AND PRIVILEGES OF ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBER STATUS RESPECTIVELY. 6. HONORARY MEMBERS. 6.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 6.B. RIGHTS OF HONORARY MEMBERS INCLUDE HAVING ALL PRIVILEGES OF FULL MEMBERS, EXCEPT THEY MAY NOT HOLD OFFICE AND ARE EXEMPT FROM PAYING MEMBERSHIP DUES. 7. MEMBER IN TRAINING MEMBERS. 7.A. MEMBER IN TRAINING MEMBERS ARE HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL WHO ARE PARTICIPATING IN A SUBSPECIALTY TRAINING PROGRAM IN ONCOLOGY OR ANOTHER FIELD THAT WOULD LEAD TO ELIGIBILITY FOR FULL OR ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERSHIP. 7.B. RIGHTS OF MEMBER IN TRAINING MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. MEMBER IN TRAINING MEMBERS MAY NOT HOLD OFFICE OR VOTE, EXCEPT THAT THEY MAY SERVE AS VOTING MEMBERS OF COMMITTEES OF ASCO. 8. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS. 8.A. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS ARE MEDICAL RESIDENTS, MEDICAL STUDENTS, GRADUATE STUDENTS, AND UNDERGRADUATE STUDENTS WHO ARE ENROLLED IN A BIOMEDICAL NURSING OR ALLIED HEALTH PROGRAM, AND WHO HAVE A PREDOMINANT INTEREST IN THE BIOLOGY, DIAGNOSIS, PREVENTION, OR TREATMENT OF HUMAN CANCER. 8.B. RIGHTS OF STUDENT/NON-ONCOLOGY RESIDENT MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS ARE NOT ELIGIBLE TO VOTE OR HOLD OFFICE OR TO SERVE AS VOTING MEMBERS OF COMMITTEES OF ASCO. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS: THE PRESIDENT, PRESIDENT-ELECT, PAST-PRESIDENT, TREASURER, AND 14 DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF); THE PRESIDENT OF INSTITUTE FOR CLINICAL EXCELLENCE, LLC (D/B/A QOPI CERTIFICATION PROGRAM AND D/B/A CANCERLINQ); AND THE PRESIDENT OF ASCO LEASING LLC. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MUST RECENTLY UNDERTAKEN IN 2012. VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATEDORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP/GC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2012. CHIEF FINANCIAL OFFICER (CFO). THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2012. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF): THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE.THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2012. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY. THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2012. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, WAS PUBLISHED IN THE JANUARY 20, 2006 EDITION OF JOURNAL OF CLINICAL ONCOLOGY (THE EDITION IS AVAILABLE TO THE PUBLIC FOR FREE), AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION A, LINE 7B: NO DECISIONS OF THE GOVERNING BODY ARE SUBJECT TO APPROVAL BY MEMBERS, STOCKHOLDERS, OR OTHER PERSONS. HOWEVER, THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 10B: ALTHOUGH ASCO HAS STATE AND REGIONAL AFFILIATES THROUGH ITS STATE AND REGIONAL AFFILIATE PROGRAM, ASCO DOES NOT HAVE THE LEGAL AUTHORITY TO EXERCISE SUPERVISION AND CONTROL OVER THEM AND EACH AFFILIATE IS A SEPARATELY INCORPORATED LEGAL ENTITY THAT IS RESPONSIBLE FOR ITS OWN FISCAL MANAGEMENT. AFFILIATES MAY NOT ACT ON BEHALF OF ASCO AND ARE PROHIBITED FROM ANY ACTION THAT MIGHT IMPLY AN AGENCY RELATIONSHIP. AFFILIATES MAY NOT BIND ASCO TO ANY CONTRACT WITH A THIRD PARTY. ASCO'S STATE AND REGIONAL AFFILIATE PROGRAM IS DESIGNED TO ASSIST STATE AND REGIONAL SOCIETIES IN ADDRESSING THE PRACTICAL ISSUES FACING PHYSICIANS WHO CARE FOR PEOPLE WITH CANCER AND TO FACILITATE AND ENCOURAGE INVOLVEMENT IN ASCO'S PUBLIC POLICY INITIATIVES. EACH AFFILIATE HAS A VOTING REPRESENTATIVE ON THE ASCO STATE AFFILIATE COUNCIL, WHICH IS INTENDED TO ADDRESS THE PRACTICE OF ONCOLOGY, WITH A PARTICULAR FOCUS ON REIMBURSEMENT FOR, ACCESS TO, AND QUALITY OF MEDICAL ONCOLOGY SERVICES. THROUGH PARTICIPATION IN THE ASCO STATE AFFILIATE COUNCIL, AFFILIATES HAVE A ROLE IN THE DEVELOPMENT OF PUBLIC POLICY POSITIONS AT THE NATIONAL LEVEL AND ALSO RECEIVES INPUT REGARDING STATE AND REGIONAL ISSUES AFFECTING ONCOLOGY. STATE AND REGIONAL SOCIETIES INTERESTED IN BEING AFFILIATES MUST SUBMIT AN APPLICATION TO ASCO THAT, AMONG OTHER THINGS, REQUIRES THEM TO DEMONSTRATE THAT THEY ARE VALIDLY INCORPORATED UNDER STATE LAW, HAVE IN PLACE GOVERNANCE PRACTICES AND PROCEDURES (BYLAWS, OFFICERS, DIRECTORS, ELECTIONS, MEETINGS, AND RESPONSIBLE FISCAL MANAGEMENT), AND HAVE PHYSICIAN MEMBERSHIP REQUIREMENTS THAT ARE CONSISTENT WITH ASCO'S STANDARDS. ASCO PROVIDES STATE AFFILIATES WITH A VARIETY OF ASSISTANCE, INCLUDING ASCO POLICY ANALYSES, ACCESS TO ASCO STAFF ON MATTERS OF INTEREST TO STATE AFFILIATES, AND ASSISTANCE WITH MEDIA AND OUTREACH. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 9: GAIN ON VALUE OF INTEREST RATE SWAP 292,558. FORM 990, PART XII, LINE 2C COMMITTEE OVERSIGHT OF THE AUDIT--ASCO HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT AUDIT FIRM. THIS PROCESS HAS NOT CHANGED FROM THE PREVIOUS YEAR. INSTITUTE FOR CLINICAL EXCELLENCE LLC 2318 MILL ROAD ALEXANDRIA VA 22314 271629211 QOPI CERTIFICATION PROGAM VA 135985 74467 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ASCO LEASING LLC 2318 MILL ROAD ALEXANDRIA VA 22314 273378225 RENTAL OF 5TH FLOOR VA 967400 292920 AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQUER CANCER FOUNDATION OF ASCO (CCF) 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 DEDICATED TO CONQUERING CANCER WORLDWIDE BY FUNDING RESEARCH VA 501 (C)(3) 509 (A)(1) 1 1 1 1 0 1 0 0 0 0 1 0 0 1 0 1 1 1 0 0 CCF A 231180 FMV CCF B 764000 FMV CCF C 9951001 FMV CCF E 64000000 FMV CCF J 231180 FMV CCF M 2034840 FMV CCF O 3143216 FMV CCF P 2603551 V CCF Q 5226278 FMV